RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to evaluate the safety and indicators of efficacy of up to 4
doses of orally administered dabigatran etexilate, administered twice daily, compared to
placebo when given in addition to dual antiplatelet treatment in patients with an index event
(MI) at high risk for new ischaemic cardiovascular events.